Saturday, April 14, 2018

Best Practices for Analyzing Pesticides and Their Metabolites in Environmental Samples

When a company wishes to commercialize a new pesticide, they must conduct environmental studies and develop analytical methods capable of detecting the pesticide, and its metabolites, in soil and water samples. The methods must be robust and rugged, for easy use in routine analysis. James Stry, a principal investigator at FMC Agricultural Solutions, recently talked to LCGC about best practices he and his team have established for developing such methods, including approaches to meeting a variety of requirements of regulatory bodies, simplifying sample preparation, dealing with matrix effects, choosing an ionization method, and streamlining method development.

When you are developing environmental methods for the registration or re-registration with the U.S. Environmental Protection Agency (EPA) of a new pesticide, what exactly do you have to demonstrate?

We must demonstrate that the methods we develop extract the environmental residue of concern from soil or sediment and that the residue is accurately quantified. To demonstrate the performance of the extraction method, we treat soil samples with radiolabeled compounds and age them in conditions representative of the environment. Aging the treated soil or sediment allows for the environmental metabolites to form and for the soil to become representative of a sample collected from the environment. We then extract the aged samples and analyze the radioactivity in the extract and the amount of radioactivity remaining in the soil. We test different extraction solvents, extraction techniques (for example, bead mill, sonication, or microwave), and the number of extractions conducted until close to all of the significant residue is extracted from the sample.

Once we have an extraction method, we fortify untreated control soil or sediment samples with known amounts of the analytes of interest. We then extract and analyze these samples and compare the concentration determined using the method to the known amount added to the control samples. The amount determined must be between 70% and 120% of the amount added for the method performance to be acceptable.

In addition to meeting the requirements of the U.S. EPA, do you also have to meet requirements for other regulatory bodies, such as those of other countries, if your products will be sold abroad, or of individual states within the United States? If so, how do you balance meeting all the requirements?

In an attempt to minimize additional method development work, we develop our methods to meet the most conservative requirements and test our methods on soil collected from all parts of the world. Currently, the European Union (EU) has some of the most conservative requirements for environmental methods. These requirements are described in the SANCO 825 Revision 8.1 guidance document (1). Once validated, the environmental methods can be sent to support compound registrations anywhere. An example is the residue method for chlorantraniliprole in crops (2). This method was validated on 21 different crops at a limit of quantitation of 0.010 mg/kg. This method has been accepted by regulatory agencies around the world for data collection and maximum residue limit (MRL) enforcement.

What are typically the biggest challenges in developing methods for detecting a pesticide and its metabolites in soil or sediment? What are the biggest challenges for detecting them in water?

Minimizing matrix effects is a major challenge when developing environmental methods. Since our methods are intended to analyze samples from grower fields, a suitable control sample will not always be available. Therefore, preparing standards in untreated control extracts may not always be an option. Moreover, the U.S. EPA prohibits the use of matrix-matched standards in all monitoring and enforcement methods (3).

Developing selective cleanup steps is one way to deal with matrix effects. However, the number and diversity of metabolites in the methods and the low limit of quantitation (1.0 µg/kg or below) makes method development a challenging task. The diversity of metabolites makes it difficult to develop one cleanup procedure capable of removing co-extracts while keeping all of the analytes of interest in a single extract. Keeping all of the compounds in a single extract limits the selectivity of the cleanup procedure.

Developing chromatographic separations using ultrahigh-pressure liquid chromatography (UHPLC) columns or solid-core particles can help minimize matrix effects as well. The sharp peak shape these columns produce lowers the instrument detection level, allowing additional dilution of the extracts. Dilution is perhaps the best way to minimize matrix effects. Instrument manufacturers continue to produce faster, more sensitive, and more-rugged instruments that have allowed us to simplify and streamline our methods. The speed of the newest generation of instruments allow for positive–negative switching without significant loss of sensitivity. This capability has removed the need to separate positive- and negative-ionizing compounds chromatographically or to analyze them in multiple chromatographic runs.

Water samples, although less complicated than soil or sediment, can be just as challenging. Water methods usually have a limit of quantitation of 0.10 µg/L or lower. For methods that include many metabolites, the analytes may need to be extracted from the water samples using solid-phase extraction (SPE) or a liquid–liquid partition step. Once the extract is concentrated, a solvent-exchange step may be needed before analysis. At the low levels analyzed in these methods, minor water contaminants can complicate quantitative analysis.

Over the years, have you developed best practices or streamlined approaches to developing these methods?

When developing the extract purification procedures, we tend to use a systematic approach. Before extracting any samples, we test evaporation and reconstitution steps, liquid–liquid partitions, and SPE procedures. When developing SPE procedures, we filter the analytes through columns in a variety of solvents to determine when they are retained and when they are eluted. Once we retain the analytes on a cartridge, we wash the cartridges with progressively stronger solvents until we have a complete profile of the properties for all analytes. Having all of this information allows us to understand how the analytes behave and to piece together an efficient and effective cleanup procedure.

We prefer to include all of the known metabolites in the methods. If the compound is not detected in the terrestrial field soil dissipation studies or if it does not show any adverse ecotoxicology effects, it can be removed from the method. We refer to this approach as comprehensive method development. We validate our methods in this manner because the addition of a new metabolite to an existing method often results in completely reworking the method, which can be time- and resource-intensive.

In environmental analysis, a challenge is often the complex matrix, which requires effective sample cleanup and preparation. Do you have “go-to” sample cleanup or preparation approaches for certain classes of products?

When developing our methods, we usually start with the most difficult soil or water samples. The idea is that if the method works for the most complex samples it will perform well for the other samples. For soil samples, we start with a high clay, high organic matter soil. We have found this combination results in an extract that is very difficult to purify and analyze. For water samples, we usually start with a pond-water sample.

The methods developed are based on the analytes included in the analysis. When developing methods for polar metabolites, some of the reversed-phase polymer SPE cartridges can be very effective at concentrating the sample extracts. We usually try to develop cleanup procedures that complement the separation and detection methods. If we are using reversed-phase LC we will try to develop an ion-exchange cleanup. If we are using an alkyl SPE cartridge (such as C18 or C8) for the cleanup step, we will develop a separation using a phenyl or biphenyl column. The overall goal is to minimize matrix effects by taking advantage of multiple physical-chemical properties of the analytes.

What percentage of your methods use gas chromatography (GC) and what percentage use LC? Has there been any change in recent years in that balance?

Almost all of the methods we develop are LC methods. Many of our active ingredients are thermally labile, limiting the use of GC analysis. The inclusion of multiple metabolites to these methods also limits the amount of GC analysis we conduct. Often, the metabolites we are analyzing are small polar alcohols or weak acids that are not amenable to GC analysis without derivatization. Although derivatization procedures can be developed, they can be time consuming and add complexity to the methods. It is also worth mentioning that relative to LC analyses, we have generally observed more severe matrix effects when conducting GC analyses.

What type of mass spectrometry (MS) detection do you typically use?

We typically use LC–MS/MS detection on triple-quadrupole instruments. Given that we are analyzing a limited number of known compounds using a reference standard, we can set up several multiple-reaction monitoring (MRM) transitions at the retention time of each analyte. In addition to being very sensitive, this approach allows for confirmation and quantitation during a single analysis. An added benefit is the availability of triple-quadrupole instruments in contract and monitoring laboratories. Using similar equipment allows for our methods to be transferred and revalidated at the laboratories performing the analysis with minimal modifications.

When do you use atmospheric pressure chemical ionization (APCI) MS, rather than electrospray ionization (ESI)?

When developing a new method, we usually start with ESI because often it is more sensitive than APCI. If we determine matrix effects are affecting method performance, we attempt to develop a cleanup procedure that is efficient and effective at minimizing the matrix effects. If, because of the number or diversity of the analytes, the cleanup procedure is not effective, is not rugged, or is very complicated, we switch to the APCI ion source. Although less sensitive, APCI usually does not exhibit the same degree of matrix effects as ESI. Given the reduced sensitivity of APCI, we adjust the injection volume, aliquot factor, or the sample’s final volume to reach the required detection level (2). Not all of the compounds we monitor can be ionized using APCI because of the increased temperature of the ion source and the gas-phase ionization mechanism. For compounds that are not amenable to APCI we return to ESI and look for new extract cleanup steps or better chromatographic separations until a robust method is developed.

How do you balance the need for sample preparation methods that are effective but not overly complicated or time consuming?

We need to strike a balance between the amount of sample cleanup, the time required to conduct the analysis, and the overall method performance. Cleanup can be time consuming and tedious work. However, without adequate cleanup, a method will perform well for only a limited number of sample types because of matrix effects or could result in false positives as a result of coeluted peaks. Reducing sample cleanup in favor of longer chromatographic separations limits the number of samples that can be analyzed per instrument each day.

Because of the large sample size (2–5 g) required to produce a representative soil or sediment sample, we have not implemented the 96-well format or other automated sample preparation approaches. We have seen significant improvements in efficiency using bead mill extractors, however. Bead mill extractors show excellent extraction efficiency of incurred residues and require less solvent per sample, and all of the equipment used is disposable, reducing the probability of sample contamination. The biggest advantage of bead mill extractors is the amount of time required to perform an extraction. An extraction requiring 20–30 min on a wrist action shaker or in a sonicating bath can be completed in 2–3 min using a bead mill.

Our goal is to develop a method with an efficient and rugged cleanup procedure and a set of chromatographic conditions that allow for adequate sample throughput without compromising the accuracy of the analysis.

References

(1) European Commission, Directorate General Health and Consumer Protection. “Guidance Document on Residue Analytical Methods,” SANCO/825/00 rev. 8.1, November 16, 2010.

(2) J. Grant, C.A. Rodgers, C.D. Chickering, S.J. Hill, and J.J. Stry, J. AOAC Int. 93(4), 1293–1301 (2010).

(3) U.S. EPA Ecological Effects Test Guidelines: OCSPP 850.6100: Environmental Chemistry Methods and Associated Independent Laboratory Validation.

Source link

Scaling LC Methods Using Superficially Porous Particle Stationary Phases

The use of ultrahigh-pressure liquid chromatography (UHPLC) is now commonplace among pharmaceutical laboratories. However, until depreciation cycles replace traditional high performance liquid chromatography (HPLC) systems that operate at a maximum pressure of 400 bar, the advantages of UHPLC cannot be realized worldwide. Thus, product methods developed using UHPLC capabilities cannot directly transfer these methods to receiving laboratories without qualified UHPLC availability. As scaling methods from traditional LC to UHPLC has been popular in recent years, the desire exists to address this LC limitation by potentially transferring methods back from UHPLC to available LC systems. This capability has not been shown to be effective on traditional LC columns. Today, pharmaceutical chromatographic methods often use superficially porous packed particle columns that enable UHPLC-like separation under 400 bar. Unlike traditional stationary phases, which use a range of particle sizes with associated column dimensions, superficially porous particle stationary phases often use the same particle size in differing column dimensions. As the particle size now remains the same, this study looks to see if reverse scaling of chromatographic profiles of interest to the pharmaceutical industry can be routinely achieved.


Liquid chromatography (LC) instrumentation operating at greater than 400 bar is becoming more commonplace as newer equipment is making its way into commercial laboratories. Although these ultrahigh-pressure liquid chromatography (UHPLC) systems are becoming more prevalent, the industry still relies on transferring chromatographic methods throughout the world and, as such, the issue that not all receiving laboratories routinely operate with LC systems that are compatible with UHPLC methods still needs to be addressed.

Since its inception, scaling low-pressure methods to UHPLC conditions has been prevalent. Many companies have scaling calculators available on their websites (1). Scaling of LC is becoming less of an issue as depreciation cycles replace laboratory LC systems with higher pressure capabilities. Yet, the issue of low-pressure systems still exists in pharma when using smaller contract and worldwide laboratories. With proper considerations for flow, injection, and system void volumes, methods developed on <400-bar systems are often made much more efficient using UHPLC conditions (2–4). However, the scaling is not perfect, and the UHPLC method should be revalidated before use. Although resolution may improve, the required lower injection volume may not place enough analyte on the column to detect low-level impurities. In addition, as demonstrated in our laboratory, columns may not behave identically as scaled (5). We found that scaling from UHPLC back to high performance liquid chromatography (HPLC) is not advantageous for impurity methods because of potential selectivity and performance issues. This observation makes sense; we don’t road test a Formula I automobile to race with a street car.

After publication of our reverse-scaling study, columns packed with superficially porous particles (SPPs) have become prevalent for pharmaceutical applications. Columns packed with these particles are often referred to as core–shell columns. Core–shell columns have the advantage of exhibiting near-UHPLC separations but at lower pressures (6). This capability enables laboratories to shorten their separation run times and efficiencies on traditional, non-UHPLC, instrumentation. Relevant to scaling interests, core–shell columns are often packed with the same particle in differing column dimensions. Unlike in the original reverse-scaling studies, core–shell columns enable the same particle to be used in the differing column dimensions. This characteristic may allow separations to reverse scale more effectively from UHPLC to HPLC conditions and pressures. The original intent of this study was to only look at vertical scaling, but the data showed right off the bat that this approach would not work. The investigation moved to horizontal scaling as a follow-up series of experiments to further investigate core–shell column scaling. In this study, a representative separation profile using commercially available drug substances was used to investigate reverse scaling with SPP columns.

Experimental

Instrumentation

The LC data reported in this study was generated using a Thermo Fisher Scientific Ultimate 3000 system equipped with a photodiode-array detector. System volume changes are critical in method scaling. A single instrument platform was used to negate this affect. Using a single system for all column investigations allowed us to operate at both traditional and UHPLC conditions and normalize the system effects and void volume differences that we would have using different systems. Thus, this study focused solely on column differences. The LC system was controlled and the resulting data were processed using Atlas Version 9.00.0.10711 (Thermo Fisher Scientific).

LC Conditions and Samples

Mobile phases and LC conditions were consistent with those used in a previous study (11). A single vendor for the traditional phase UHPLC column and two separate vendors for the SPP phases were used. All target analytes and mobile phases were prepared with chemicals purchased from Sigma-Aldrich. The LC column dimensions that were used are listed in Table I.

Scaling Calculator

Scaling calculations were calculated as described in the manuscript and correlated with spreadsheets received from Grace Discovery Sciences. The use of method translation calculators was recently reviewed by Majors (8).

Results and Discussion

Scaling Calculations

Scaling calculators were created for projecting the run conditions moving from traditional HPLC column formats to UHPLC column formats. In this regard, the calculators work well in speeding up run times from traditional HPLC methods and oftentimes improving, or at least maintaining resolution, throughout the profile (2,3). Because many laboratories still use equipment limited to the traditional HPLC platform, laboratories have attempted to scale back from UHPLC to HPLC with the goal of rapid HPLC method development on the UHPLC platform and transferring the method on traditional platforms that are still being used. Webster and Elliott showed why this approach may not be a good idea (5). This issue is limited in scope as depreciation cycles equip more and more laboratories with UHPLC-compatible instruments. Scaling calculators are designed with the conversion from HPLC to UHPLC in mind. The critical parameters in scaling from UHPLC to HPLC include column length, particle size, and injection volume (5,9–11). Neue and colleagues (12) demonstrated the scaling of separations using 5-µm, 15-cm columns to 1.7-µm, 5-cm columns. Dramatic changes should be made only if the chromatographic profile and resolution of the critical pair is maintained (13).

Scaling calculations are based on standard chromatographic concepts (14). The primary equations used by the scaling calculators are

Injection volume:

where I is the injection volume for methods 1 and 2; d c is the column diameter used in methods 1 and 2; and L is the column length used for the method 1 and 2 columns.

Flow rate:

where F is the flow rate for methods 1 and 2; d c is the column diameter used in methods 1 and 2; and d p is the particle size used for the method 1 and 2 columns.

Gradient time:

where T is the gradient time for methods 1 and 2.

The calculations are designed to provide starting chromatographic conditions followed by further optimization. The critical parameter in reverse scaling is whether these conditions yield a pressure under the pressure maximum for HPLC. Most traditional HPLC platforms tolerate pressure of up to 400 bar. A UHPLC method that is to be converted to an HPLC platform must first be optimized to run at conditions that project that the new method pressure will remain under 400 bar. This often entails slowing down the optimized UHPLC method (5,14).


Figure 1: Study profile on traditional and superficially porous particle phases: (a) traditional UHPLC (50 mm × 2.0 mm, 1.5 µm), (b) Core–shell A (50 mm × 2.1 mm, 2.6 µm), and (c) Core–shell B (50 mm × 2.1 mm, 2.7 µm). Gradient conditions are given in Table II. Peaks: 1 = furosemide,2 = carbamazepine, 3 = naproxen, 4 = valsartan, 5 = ibuprofen, 6 = indomethacin.

Study

The goal of this study was to evaluate whether columns packed with core–shell particles reverse scale more effectively than traditional column packings. A separation based on earlier work (5) was used for actual UHPLC separation using compounds that vary in their chemical nature. In that study, the UHPLC column in a traditional particle format was used as the basis to investigate scaling back to HPLC.

Horizontal Scaling from UHPLC to Core–Shell Particles

Our first attempt is looking at UHPLC to short SPP columns. In Figure 1a, the rapid resolution of varying drug substances on a traditional UHPLC phase is presented. If we cannot scale a representative profile from traditional UHPLC to core–shell UHPLC phases, going to core shell phases packed in traditional lower pressure column dimensions is not warranted. Using the horizontal scaling conditions from Table II, the resulting profile for the 2.6-µm Core–shell A phase is shown in Figure 1b. In this separation, a peak reversal for the carbamazepine and furosemide pair is seen as well as a loss in resolution. Additionally, ibuprofen is coeluted with the indomethacin peak. It is not possible to conclude that scaling yielded an equivalent profile with the Core–shell A column and conditions. Looking at the results obtained using a second core–shell column (from a different manufacturer) in Figure 1c, the resulting profile again exhibits peak reversal and loss of resolution for the carbamazepine and furosemide peak pair. In addition, a coelution of the ibuprofen and indomethacin peak pair can be seen in the profile. Again, an equivalent profile was not produced. The effect of scaling may not be the culprit here as much as the older, traditional stationary phase (type A silica) likely has more exposed silica. It should be noted that using calculators specifically from the Core–shell A and B vendors for their phases did not solve this issue. Looking into this stationary phase effect a little further, the mobile phase was changed from formic acid to trifluoroacetic acid to investigate whether the addition of an ion-pairing reagent would improve the core–shell profile. Figure 2a is the resulting profile adding 0.1% trifluoroacetic acid in place of formic acid used with the traditional phase UHPLC column. Essentially the same profile is produced. However, the profile improves for both SPP phases (Figures 2b and 2c). The ibuprofen peak resolution with the core shell particles remains unacceptable. It is likely with further optimization that the profile could be obtained on the SPP phases. Method optimization is not direct method scaling of the separation. What this data shows is not so much that scaling cannot be achieved, but in more-complex separations the differences in stationary phase chemistries still remain significant. As with all LC separations, the nature of the stationary phase and the chemistry of the analytes must be considered. The United States Pharmacopeia (USP) may traditionally allow the substitution of one C18 column for another, but this equivalence is seldom realized in industrial pharma (16).


Figure 2: Study profile using trifluoroacetic acid on traditional and SPP phases: (a) Traditional UHPLC (50 mm × 2.0 mm, 1.5 µm), (b) Core–shell A (50 mm × 2.1 mm, 2.6 µm), and (c) Core–shell B (50 mm × 2.1 mm, 2.7 µm). Gradient conditions are given in Table II. Peaks: 1 = furosemide,2 = carbamazepine, 3 = naproxen, 4 = valsartan, 5 = ibuprofen, 6 = indomethacin.

Vertical Scaling with Core–Shell Particles

One of the advantages of superficially porous particles, according to their vendors, is that because the same particle is used in different column dimensions, scaling with these phases should be straightforward. Rather than looking at a horizontal scaling from the UHPLC short column as we did before, now we are changing the optimal core–shell conditions and scaling back to traditional HPLC column dimensions. We are going to start with the separation on the short SPP column and see how it vertically scales back to columns with dimensions compatible with lower pressure systems (Table III). Figure 3a is our initial separation for the Core–shell A phase. Ibuprofen was left in the sample matrix to see if the conditions applied will ultimately resolve this peak from the indomethacin peak. Increasing column dimensions, shown in Figures 3b–3e, effectively maintains the original profile. Interestingly, going down to the 1.7-µm particles did not enhance resolution of the original profile. The resolution data for the separations is presented in Table IV and the relative retention times (RRT) are listed in Table V. The RRTs are close, but not acceptably equivalent to say that the profiles scaled equivalently for both the 2.6- and 5-µm particles. From this data, we conclude that the scaling was a good estimate of the conditions needed for the different column geometries. However, there is still enough error in particle composition and packing differences so that direct method scaling was not achieved.


Figure 3: Vertical scaling on Core–shell A SPP phases. (a) 50 mm × 2.1, 2.6 µm, (b) 150 mm × 3.0 mm, 2.6 µm, (c) 150 mm × 4.6 mm, 2.6 µm, (d) 150 mm × 4.6, 5 µm, and (e) 250 mm × 4.6 mm, 5 µm. Gradient conditions are given in Table III. Peaks: 1 = furosemide,2 = carbamazepine, 3 = naproxen, 4 = valsartan, 5 = ibuprofen, 6 = indomethacin.

The vertical scaling study was repeated with columns from a second core–shell column manufacturer, designated as the Core–shell B phase (Table VI). Again, illustrated in Figure 4a, an initial resolution profile for this phase was established. The increasing column dimensions seen in Figures 4b–4e actually improve the profile for the carbamazepine and furosemide peak pair as well as the indomethacin and ibuprofen peak pair to a lesser extent. The resolution and RRT data for this study are presented in Tables VII and VIII. The RRT data are much improved with this series of profiles. It remains difficult to argue that the scaling profile was maintained.


Figure 4: Vertical scaling on Core–shell B SPP phases. (a) 50 mm × 2.1, 2.7 µm, (b) 150 mm × 3.0 mm, 2.7 µm, (c) 150 mm × 4.6 mm, 2.7 µm, (d) 150 mm × 4.6, 5 µm, and (e) 250 mm × 4.6 mm, 5 µm. Gradient conditions given in Table VI. Peaks: 1 = furosemide,2 = carbamazepine, 3 = naproxen, 4 = valsartan, 5 = ibuprofen, 6 = indomethacin.

Conclusion

Column scaling in liquid chromatography is an interesting concept that may work for series of analytes with consistent chemistry. However, the real value in scaling chromatographic methods is attempting to improve challenging lower-pressure separations using UHPLC capability. In our laboratory we have not seen stationary phases scale theoretically with column dimension. Scaling has not proven to be an achievable opportunity for most complex pharmaceutical separations. It is our suggestion to improve chromatographic efficiencies using core–shell and UHPLC technologies in a standalone fashion that can be optimized using scaling principals. However, revalidation is required to establish equivalence because direct scaling is not adequate in the cases studied.

Disclosure

This project was supported by AbbVie, Inc. AbbVie, Inc. participated in the interpretation of data, writing, reviewing, and approving the publication. Gregory K. Webster is an employee of AbbVie and Matthew A. Gragg is a contractor with AbbVie, Inc.

References

(1) Sigma, https://ift.tt/2HMGXUb, Sciences Analytiques: https://ift.tt/2G6XyF0; ACD Labs: https://ift.tt/2G07QDw.

(2) J.W. Dolan, LCGC North Am. 32(2), 98–102 (2014).

(3) J.W. Dolan, LCGC North Am. 32(3), 188–193 (2014).

(4) M. Swartz, “HPLC to UPLC Method Migration: An Overview of Key Considerations and Available Tools,” presented at the Pittsburgh Conference & Exposition on Analytical Chemistry and Applied Spectroscopy (Pittcon), Chicago, Illinois, 2007.

(5) G.K. Webster and A. Elliott, Am. Pharm. Rev. 14, 32–40 (2011).

(6) V. González-Ruiz, A.I. Olives, and A. Martín, TrAC, Trends Anal. Chem. 64, 17-28 (2015).

(7) I. Baranowska and B. Kowalski, Water Air Soil Pollut. 211, 417–425 (2010).

(8) R.E. Majors, LCGC North Am. 29(6), 476–484 (2011).

(9) D. Guillarme, D.T.T Nguyen, S. Rudaz, and J.L. Veuthey, Eur. J. Pharm. Sci. 66, 475–482 (2007).

(10) D. Guillarme, D.T.T Nguyen, S. Rudaz, and J.L. Veuthey, Eur. J. Pharm. Biopharm. 68, 430–440 (2008).

(11) M.M. Dittmann, “Approaches Towards Method Compatibility Between HPLC and UHPLC Systems,” Paper 1970-6, presented at the Pittsburgh Conference & Exposition on Analytical Chemistry and Applied Spectroscopy (Pittcon), Orlando, Florida, 2010.

(12) U.D. Neue, D. McCabe, V. Ramesh, V. H. Pappa, and J. DeMith, Pharmacopeial Forum 35, 1622–1626 (2009).

(13) G.K. Webster and C.L. Basel, LCGC North Am. 21(3), 286–294 (2003).

(14) G.K. Webster, T.F. Cullen, and L. Kott, Ultra-High Performance Liquid Chromatography and Its Applications, (Wiley Interscience, 2013), pp. 31–54.


Gregory Webster is a senior principal research scientist in Development Sciences at AbbVie, Inc. Dr. Webster received his PhD in analytical chemistry at Northern Illinois University in 1991. Prior to joining Abbott/AbbVie in 2007, he worked at Alpharma, Chemsyn Laboratories, Bayer Corporation, and Pfizer.

Matthew Gragg is currently a chemist working within the NCE Analytical R&D – LC group at AbbVie, Inc. He graduated with a BS in Chemistry from Truman State University in 2015.

Direct correspondence to: [email protected]

Source link